Luciano Costa, MD, PhD, Discusses Results That Surprised Him From the MASTER Trial in Multiple Myeloma
Luciano Costa, MD, PhD, spoke about how the results in the final primary analysis of the MASTER trial with daratumumab, carfilzomib, lenalidomide, and dexamethasone in multiple myeloma were not what he expected.
At the 2021 American Society of Hematology Annual Meeting, Luciano Costa, MD, PhD, the Aassociate dDirector for Clinical Research at O’Neal Comprehensive Cancer Center, discussed which results of the MASTER trial (NCT03224507) he was most surprised to see when of patients with multiple myeloma who were treated with daratumumab (Darzalex), carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone and what he was most surprised to see come from the data.
Transcript:
The primary end point of this trial was minimal residual disease [MRD] at 10-5. The surprising part was that [rate] was very high, about 80%, irrespective of risk. That part was the same with patients [who had] 0, 1, or 2 or more high-risk chromosomal abnormalities, and that was a bit surprising. The differences start occurring when you look at [MRD] 10-6; achievement of that was lower in patients with 2 or more high-risk abnormalities. The timing was [also] different and very few of those patients achieved MRD at 10-6 after just induction and most of those did so after transplant. We have progression-free survival [PFS] in 95% of the patients with 0 to 1 high-risk abnormalities. Most of those patients are now off therapy and that part is intriguing. Hopefully, it will inform the design of future trials.
Reference
Costa L, Chhabra S, Medvedova E, et al. Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted treatment cessation. Final primary end point analysis of the Master Trial. Presented at: 63rd American Society of Hematology Annual Conference. December 11-14. Abstract 481. Accessed December 7, 2021. https://bit.ly/3GozUPK
